Share Twitter LinkedIn Facebook Email Shyamala Navada, M.D. Assistant Professor at Mount Sinai Health System Discusses Oral Rigosertib With Standard Dose Azacitidine At The 60th ASH Annual Meeting on Dec 1, 2018.
Inotuzumab Ozogamicin and Gemtuzumab Ozogamicin: A 2024 Guide to Managing Liver Toxicity and Cancer Treatment for Oncologists [40 Slides] Hematologic Malignancies 5 Mins Read
Non-Malignant Hematology Clinics: Essential Pioneers in the Evolving Hematologic Care Hematologic Malignancies 3 Mins Read
Spotlight on CAR T-cell Therapy in 2024: Advances & Clinical Insights Acute Lymphoblastic Leukemia 3 Mins Read